Nintedanib

May 18, 2016May 18, 2016

Efficacy and Safety of Ofev (Nintedanib) as IPF Treatment Supported by New Analyses

Boehringer Ingelheim Pharmaceuticals presented 12 idiopathic pulmonary fibrosis (IPF)-related abstracts at the recent American Thoracic Society (ATS) 2016 Annual Conference, including further analyses of its INPULSIS clinical trial program, which added to the ... Read more

February 29, 2016May 13, 2016

Ofev (Nintedanib) Slows IPF Disease Progression, According to Analysis of Studies

Idiopathic Pulmonary Fibrosis, News

An analysis of the Phase II TOMORROW trial and two Phase III INPULSIS trials (INPULSIS-1 and INPULSIS-2), analyzing the safety and efficacy outcomes for Ofev (nintedanib, developed by Boehringer Ingelheim), revealed that ... Read more

January 29, 2016February 3, 2016

British Health Institute Recommends OFEV for Adults with IPF

Idiopathic Pulmonary Fibrosis, News

Boehringer Ingelheim recently announced that the British National Institute for Health and Care Excellence (NICE) has recommended OFEV (nintedanib) as a therapy for adult patients with idiopathic pulmonary fibrosis (IPF) within the National ... Read more

December 15, 2015December 15, 2015

New IPF Study to Test OFEV/Esbriet as Combination Therapy

Idiopathic Pulmonary Fibrosis, News

Boehringer Ingelheim announced that it has initiated a 12-week clinical trial investigating the safety, tolerability, and pharmacokinetics of pirfenidone (marketed as Esbriet by Genentech) as an add-on to treatment with OFEV (nintedanib). The ... Read more

December 10, 2015December 10, 2015

Phase 3 Trial for Systemic Sclerosis with Lung Fibrosis Enrolls 1st Patient

News, Scleroderma

Boehringer Ingelheim announced the enrollment of the first patient in its global, double-blind, randomized and placebo-controlled SENSCIS Phase 3 clinical trial. The trial (NCT02597933), is open for patient recruitment, and is evaluating the safety ... Read more

October 29, 2015November 5, 2015

Boehringer Reports Efficacy of OFEV in Idiopathic Pulmonary Fibrosis Studies

Idiopathic Pulmonary Fibrosis, News

Boehringer Ingelheim Pharmaceuticals, Inc., recently presented post-hoc analyses from the Phase III INPULSIS™ clinical trials at the American College of Chest Physicians Annual Meeting (CHEST 2015) in Montreal, Canada. Results ... Read more

September 22, 2015November 6, 2015

Boehringer Ingelheim to Present New Data for COPD, IPF and Asthma at European Respiratory Society International Congress

Asthma, Idiopathic Pulmonary Fibrosis, News

Boehringer Ingelheim plans to roll out several major presentations focusing for its respiratory disease portfolio at the upcoming European Respiratory Society (ERS) International Congress, September 26-30. The German company is currently ... Read more

July 16, 2015November 5, 2015

Boehringer Ingelheim Lauds 2015 IPF Treatment Guidelines for Recommending OFEV

Idiopathic Pulmonary Fibrosis, News

The recently published 2015 ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis – An Update of the 2011 Guideline, which recommends using OFEV® (nintedanib) to treat patients diagnosed with idiopathic pulmonary fibrosis ... Read more

May 19, 2015November 5, 2015

Boehringer’s Idiopathic Pulmonary Fibrosis Therapy OFEV Shown To Be Safe, Effective in Longer-Term Study

Idiopathic Pulmonary Fibrosis, News

Boehringer Ingelheim recently announced new data on OFEV® (nintedanib) that further supports its efficacy, tolerability and safety in patients with idiopathic pulmonary fibrosis (IPF). The results were presented at the American ... Read more

January 19, 2015November 5, 2015

OFEV® (nintedanib*) Approved By The EU For Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis, News

Boehringer Ingelheim today announced that nintedanib has been approved by the European Commission (EC) for the treatment of idiopathic pulmonary fibrosis (IPF), joining the recent approval by the FDA in the U.S. back in October of ... Read more